- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01230840
Effect of Wheat Dextrin on Calcium and Magnesium Absorption (Benefiber)
October 28, 2010 updated by: Creighton University
To compare calcium and magnesium absorption within subjects with and without chronic consumption of wheat dextrin.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subjects will be generally healthy Caucasian females aged 19 and older with no known abnormalities of gastrointestinal function, and taking no medications that might alter absorptive performance. BMI will be between 19 and 31 kg/m2
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
|
cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
|
|
Experimental: wheat dextrin
wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
|
5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Calcium Absorption
Time Frame: within 2-4 weeks
|
The calcium load to be tested will be 300 mg calcium from calcium and vitamin D fortified TropicanaTM orange juice extrinsically labeled with ≈3-7 μCi of 45Ca.
The labeled orange juice will be ingested as part of a light meal, served as breakfast, after an overnight fast.
|
within 2-4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Magnesium absorption
Time Frame: within 2-4 weeks
|
The magnesium load to be tested will be from calcium and vitamin D fortified TropicanaTM orange juice extrinsically labeled with 30 mg 26Mg.
The labeled orange juice will be ingested as part of a light meal, served as breakfast, after an overnight fast.
|
within 2-4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Laura Armas, MD, Creighton University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
June 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
October 28, 2010
First Submitted That Met QC Criteria
October 28, 2010
First Posted (Estimate)
October 29, 2010
Study Record Updates
Last Update Posted (Estimate)
October 29, 2010
Last Update Submitted That Met QC Criteria
October 28, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-15249
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colonic Inertia
-
Istanbul Arel UniversityRecruitingConstipation | Colonic Inertia | DyscheziaTurkey
-
Beth Israel Medical CenterWyeth is now a wholly owned subsidiary of PfizerWithdrawn
-
Washington University School of MedicineRecruitingBehavior | Process, Acceptance | Inertia of AccommodationUnited States
-
University of ZurichLokman Hekim Üniversitesi; Elixir PharmaceuticalsCompletedCaffeine | Placebo | Sleep InertiaSwitzerland
-
University of Notre DameWithdrawnStress | Sleep | Sleep Inertia
-
Essilor InternationalRecruitingAccommodation Disorder | Accommodative Fatigue | Accommodative InertiaFrance
-
Centre Hospitalier Universitaire de NīmesTerminated
-
Baylor Research InstituteCompletedUterine AtonyUnited States
-
Cynthia WongCompletedUterine Atony With HemorrhageUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States